Trump Delays Drug Tariffs, Targets Companies Refusing US Production
US President Donald Trump's tariffs on pharmaceutical imports have caused concern among industry associations. Initially announced for October 1, the tariffs have now been delayed, with new measures targeting companies that refuse to relocate production or lower prices.
Last week, President Trump surprised experts by announcing 100% tariffs on imported branded and patented medicines, set for October 1. Pharmaceutical associations, such as Interpharma, have warned of significant risks, describing it as an 'ultimate wake-up call'.
Initially, manufacturers could avoid the tariffs by building a US production facility. However, details on this option remain unclear. Analysts believe Swiss companies are well-prepared, thanks to their existing US investments. Roche and Novartis have already planned substantial investments in the US, totalling $73 billion over the next five years.
Instead of the previously planned tariffs, the US government is now preparing measures against companies that refuse to relocate production or lower prices. Swiss pharmaceutical companies, with their significant US investments, are closely monitoring the situation. The new tariffs, set for October 1, 2025, could have far-reaching implications for the industry.
